In this study, the researchers found that the growth of new metastases in the formation of lymph nodes does not require the action of new blood vessels. These new metastases can use existing blood vessels for nutrient supply. Lymph nodes are a common site of metastasis in the spread of cancer.

For most types of solid tumors, the formation of lymph node metastases marks a higher degree of malignancy, requiring chemotherapy and other systemic therapies to treat cancer on a systemic scale. However, the true role of lymph node metastases in cancer transmission has been controversial. Some experts believe that lymph node metastases represent a kind of ability to spread the primary tumor itself, while others believe that the formation of lymph node metastases is the tumor to the body. The most critical step in the process of site metastasis, with metastatic cancer cells entering the blood circulatory system through lymph nodes, spreading the cancer species.

In a previous study, the researchers found that anti-angiogenic therapy did not prevent the occurrence and growth of lymph node metastases, but in this study, researchers first discovered lymph node development and growth using a new tumor mouse model. There was no development of new blood vessels during the process, and some angiogenesis-inducing factors and some angiogenesis-related gene expression levels in lymph node metastases did not increase. The researchers also analyzed lymph node metastases in patients with colon and head and neck cancer, and found no evidence of angiogenesis.

The researchers also treated the mouse model with two different angiogenesis inhibitors, and found no changes in vessel density and lymphocyte growth. Finally, the researchers compared the lymph node metastases of colon cancer patients who had undergone anti-angiogenic therapy with those of colon cancer patients who did not receive this treatment. The results showed that there was no difference in vascular density between the two lymph node metastases.

Overall, this study suggests that anti-angiogenic drugs have no effect in inhibiting the formation of new lymph node metastases because no angiogenesis occurs during lymph node metastasis formation, which provides important clinical treatment for cancer and drug selection. information.